licensed The University of Manchester
Intellectual Property’s (UMIP) exciplex technology. Under the terms of the license, Link will manufacture and sell exciplex-based diagnostic reagents worldwide.
Exciplex technology offers ultra-biospecificity and increases detection sensitivity over conventional systems due to negligible background signal, according to UMIP. Researchers from the university developed new exciplex diagnostic probes based on labeling oligonucleotides with exciplex partners that form excited-state complexes in close spatial proximity. Application of these modified oligonucleotides in diagnostic systems has been shown to discriminate DNA mutations at the level of PCR products and plasmid DNA, UMIP scientists claim.